Alaunos Therapeutics, Inc.

NasdaqCM:TCRT Stock Report

Market Cap: US$29.8m

Alaunos Therapeutics Past Earnings Performance

Past criteria checks 0/6

Alaunos Therapeutics's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 53.6% per year.

Key information

-25.3%

Earnings growth rate

-26.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate53.6%
Return on equity-262.3%
Net Margin-243,040.0%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

Revenue & Expenses Breakdown
Beta

How Alaunos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:TCRT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-36130
30 Jun 233-37120
31 Mar 233-38130
31 Dec 223-38130
30 Sep 223-40120
30 Jun 220-54160
31 Mar 220-67220
31 Dec 210-79260
30 Sep 210-90330
30 Jun 210-87320
31 Mar 210-83300
31 Dec 200-80280
30 Sep 200-73250
30 Jun 200-127230
31 Mar 200-123210
31 Dec 190-118200
30 Sep 19092180
30 Jun 190148180
31 Mar 190145180
31 Dec 180137200
30 Sep 182-76190
30 Jun 183-75180
31 Mar 185-75170
31 Dec 176-73150
30 Sep 176-70140
30 Jun 176-67140
31 Mar 176-180140
31 Dec 167-172140
30 Sep 167-167140
30 Jun 167-171140
31 Mar 166-54170
31 Dec 154-120180
30 Sep 153-121170
30 Jun 152-109170
31 Mar 151-100130
31 Dec 141-32120
30 Sep 141-30120
30 Jun 141-41120
31 Mar 141-54130
31 Dec 131-57140
30 Sep 131-78160
30 Jun 131-80170
31 Mar 131-84180

Quality Earnings: TCRT is currently unprofitable.

Growing Profit Margin: TCRT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TCRT is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare TCRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TCRT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: TCRT has a negative Return on Equity (-262.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.